Release – CoreCivic Announces 2023 First Quarter Earnings Release and Conference Call Dates

Research News and Market Data on CXW

April 20, 2023

PDF Version

BRENTWOOD, Tenn., April 20, 2023 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2023 first quarter financial results after the market closes on Wednesday, May 3, 2023. A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, May 4, 2023.

To participate via telephone and join the call live, please register in advance here https://register.vevent.com/register/BI6394fffe952b47d497a2735e53d08f32. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.

Participants may access the audio-only webcast of the conference call from the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. A replay of the webcast will be available for seven days.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact: Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Alliance Resource Partners, L.P. Reschedules Start Time for First Quarter 2023 Earnings Conference Call on May 2, 2023

Research News and Market Data on ARLP

Company Release – 4/20/2023 7:00 AM ET

TULSA, Okla.–(BUSINESS WIRE)– Alliance Resource Partners, L.P. (NASDAQ: ARLP) will report its first quarter 2023 financial results before the market opens on Tuesday, May 2, 2023, as previously announced. In order to best accommodate analysts’ and investors’ ability to participate in the Company’s conference call, Alliance management will now host its first quarter conference call beginning at 11:00 a.m. Eastern that same day.

To participate in the conference call, dial (877) 407-0784 and request to be connected to the Alliance Resource Partners, L.P. earnings conference call. International callers should dial (201) 689-8560 and request to be connected to the same call. Investors may also listen to the call via the “investor relations” section of ARLP’s website at www.arlp.com.

An audio replay of the conference call will be available for approximately one week. To access the audio replay, dial U.S. Toll Free (844) 512-2921; International Toll (412) 317-6671 and request to be connected to replay using access code 13737890.

About Alliance Resource Partners, L.P.

ARLP is a diversified energy company that is currently the largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is evolving and positioning itself as a reliable energy partner for the future by pursuing opportunities that support the advancement of energy and related infrastructure.

News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission (“SEC”), are available at www.arlp.com. For more information, contact the investor relations department of ARLP at (918) 295-7673 or via e-mail at investorrelations@arlp.com.

Cary P. Marshall
Senior Vice President and Chief Financial Officer
(918) 295-7673
investorrelations@arlp.com

Source: Alliance Resource Partners, L.P.

Onconova Therapeutics (ONTX) – Data Presented on Narazaciclib Targets and Mechanisms


Thursday, April 20, 2023

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data Presented At AACR Annual Meeting. Onconova presented two posters at the American Association of Cancer Research annual meeting, held April 14 to April 19. These posters from preclinical studies gave additional details on the activity, targets, and mechanism of action for narazaciclib, its CDK4/6 inhibitor, and comparisons with other approved CDK4/6 inhibitors.

Study On Naraciclib Targets. The first poster showed that narazaciclib inhibits CDK4/6 as well as additional kinases in cancer progression and metastasis. Data included the BUB1 kinase that is overexpressed in breast and uterine cancers, showing correlations between BUB1 expression and poor survival. BUB1 was inhibited by narazaciclib, but not palbociclib (Ibrance, from Pfizer) or abemaciclib (Verzenio, from Lilly). The poster also presented data showing that narazaciclib may lead to the expression of immune modulators in tumor cells that lead to anti-tumor immunity, an important mechanism for preventing recurrence.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Direct Digital Holdings (DRCT) – Raising Estimates


Thursday, April 20, 2023

Michael Kupinski, Director of Research – Digital, Media & Technology Analyst, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Revenue restatement. Certain invoices were not sent in a timely manner and roughly $1.4 million in revenue was not captured in its preliminary 2022 full year results. As such, full year revenue was $89.4 million rather than $88.0 million, as previously reported, and adj. EBITDA was $10.1 million rather than $8.8 million.

Favorable operating momentum. The restatement positively impacted 2022 results and, importantly, management re-iterated full year 2023 guidance of revenue between $118 million to $122 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Covert Threat of Antibiotic Tolerance

Image Credit: Matthias Pastwa (Flickr)

Looming Behind Antibiotic Resistance is Another Bacterial Threat – Antibiotic Tolerance

Have you ever had a nasty infection that just won’t seem to go away? Or a runny nose that keeps coming back? You may have been dealing with a bacterium that is tolerant of, though not yet resistant to, antibiotics.

Antibiotic resistance is a huge problem, contributing to nearly 1.27 million deaths worldwide in 2019. But antibiotic tolerance is a covert threat that researchers have only recently begun to explore.

Antibiotic tolerance happens when a bacterium manages to survive for a long time after being exposed to an antibiotic. While antibiotic-resistant bacteria flourish even in the presence of an antibiotic, tolerant bacteria often exist in a dormant state, neither growing nor dying but putting up with the antibiotic until they can “reawaken” once the stress is gone. Tolerance has been linked to the spread of antibiotic resistance.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Megan Keller, Ph.D. Candidate in Microbiology, Cornell University.

I am a microbiologist who studies antibiotic tolerance, and I seek to uncover what triggers tolerant bacteria to enter a protective dormant slumber. By understanding why bacteria have the ability to become tolerant, researchers hope to develop ways to avoid the spread of this ability. The exact mechanism that sets tolerance apart from resistance has been unclear. But one possible answer may reside in a process that has been overlooked for decades: how bacteria create their energy.

Cholera and Antibiotic Tolerance

Many antibiotics are designed to break through the bacteria’s outer defenses like a cannonball through a stone fortress. Resistant bacteria are immune to the cannonball because they can either destroy it before it damages their outer wall or change their own walls to be able to withstand the impact.

Tolerant bacteria can remove their wall entirely and avoid damage altogether. No wall, no target for the cannonball to smash. If the threat goes away before too long, the bacterium can rebuild its wall to protect it from other environmental dangers and resume normal functions. However, it is still unknown how bacteria know the antibiotic threat is gone, and what exactly triggers their reawakening.

My colleagues and I at the Dörr Lab at Cornell University are trying to understand processes of activation and reawakening in the tolerant bacteria responsible for cholera, Vibrio cholerae. Vibrio is rapidly evolving resistance against various types of antibiotics, and doctors are concerned. As of 2010, Vibrio is already resistant to 36 different antibiotics, and this number is expected to continue rising.

To study how Vibrio develops resistance, we chose a strain that is tolerant to a class of antibiotics called beta-lactams. Beta-lactams are the cannonball sent to destroy the bacteria’s fortress, and Vibrio adapts by activating two genes that temporarily remove its cell wall. I witnessed this phenomenon using a microscope. After removing its cell wall, the bacteria activate even more genes that morph it into fragile globs that can survive the effects of the antibiotic. Once the antibiotic is removed or degraded, Vibrio returns to its normal rod shape and continues to grow.

In people, this process of tolerance is seen when a doctor prescribes an antibiotic, typically doxycycline, to a patient infected with cholera. The antibiotic temporarily seems to stop the infection. But then the symptoms start back up again because the antibiotics never fully cleared the bacteria in the first place.

The ability to revert back to normal and grow after the antibiotic is gone is the key to tolerant survival. Exposing Vibrio to an antibiotic for a long enough time would eventually kill it. But a standard course of antibiotics often isn’t long enough to get rid of all the bacteria even in their fragile state.

However, taking a medicine for a prolonged period can harm healthy bacteria and cells, causing further discomfort and illness. Additionally, misuse and extended exposure to antibiotics can increase the chances of other bacteria residing in the body becoming resistant.

Other Bacteria Developing Tolerance

Vibrio isn’t the only species to exhibit tolerance. In fact, researchers have recently identified many infectious bacteria that have developed tolerance. A bacteria family called Enterobacteriaceae, which include major food-borne disease pathogens Salmonella, Shigella and E. coli, are just a few of the many types of bacteria that are capable of antibiotic tolerance.

As every bacterium is unique, the way one develops tolerance seems to be as well. Some bacteria, like Vibrio, erase their cell walls. Others can alter their energy sources, increase their ability to move or simply pump out the antibiotic.

I recently found that a bacterium’s metabolism, or the way it breaks down “food” to make energy, may play a significant role in its ability to become tolerant. Different structures within a bacterium, including its outer wall, are made of specific building blocks like proteins. Stopping the bacterium’s ability to craft these pieces weakens its wall, making it more likely to take damage from the outside environment before it can take the wall down.

Tolerance and Resistance are Connected

Although there has been considerable research on how bacteria develop tolerance, a key piece of the puzzle that has been neglected is how tolerance leads to resistance.

In 2016, researchers discovered how to make bacteria tolerant in the laboratory. After repeated exposure to different antibiotics, E. coli cells were able to adapt and survive. DNA, the genetic material containing instructions for cell function, is a fragile molecule. When DNA is damaged rapidly by stress, such as antibiotic exposure, the cell’s repair mechanisms tend to mess up and cause mutations that can create resistance and tolerance. Because E. coli is similar to many different types of bacteria, these researchers’ findings revealed that, ironically, essentially any bacteria can develop tolerance if pushed to their limits by the antibiotics meant to kill them.

Another recent key discovery was that the longer bacteria remain tolerant, the more likely they are to develop mutations leading to resistance. Tolerance allows bacteria to develop a resistance mutation that reduces their chances of being killed during antibiotic treatment. This is especially relevant to bacterial communities often seen in biofilms that tend to coat high-touch surfaces in hospitals. Biofilms are slimy layers of bacteria that ooze a protective jelly that makes antibiotic treatment difficult and DNA sharing between microbes easy. They can induce bacteria to evolve resistance. These conditions are thought to mimic what could be happening during antibiotic-treated infections, in which many bacteria are living next to one another and sharing DNA.

Researchers are calling for more research into antibiotic tolerance with the hope that it will lead to more robust treatments in both infectious diseases and cancers. And there is reason to be hopeful. In one promising development, a mouse study found that decreasing tolerance also reduced resistance.

Meanwhile, there are steps everyone can take to aid in the battle against antibiotic tolerance and resistance. You can do this by taking an antibiotic exactly as prescribed by a doctor and finishing the entire bottle. Brief, inconsistent exposure to a medicine primes bacteria to become tolerant and eventually resistant. Smarter use of antibiotics by everyone can stop the evolution of tolerant bacteria.

What the Marijuana Bill Aims to Resolve

Will Marijuana Stocks Regain Energy if this Federal Bill Passes?

Federal legalization concerning medical and recreational marijuana would go a long way to light up the companies that now operate legally under state laws. A group of bipartisan lawmakers in Washington refiled a bill last week to regain momentum toward national cannabis legalization. The incremental reform would direct the attorney general to create a commission for the purpose of making recommendations on a regulatory system for cannabis modelled from alcohol laws and oversight.

On April 13, the PREPARE Act (Preparing Regulators Effectively for a Post-Prohibition Adult-Use Regulated Environment Act) was presented by Rep. Dave Joyce (R-OH) and House Minority Leader Hakeem Jeffries (D-NY). The bill sponsored by this senior House Democrat along with a Republican lawmaker is intended to lay the groundwork for federal marijuana legislation.

“With nearly every state adopting its own set of cannabis reforms, an end to federal cannabis prohibition is inevitable,” Joyce, co-chair of the Congressional Cannabis Caucus, said in a press release.

“Now is the time for the federal government to respect the will of our constituents and begin the conversation on fair and effective cannabis regulation,” he said. “The PREPARE Act will give lawmakers a bipartisan platform to legislate not only a fair and responsible end to prohibition but also a safer future for our communities.”

The prospects of comprehensive marijuana legalization advancing in the Republican-controlled House this session will not be without heated debate, but certain members have expressed confidence that modest reform could be achievable on a bipartisan basis. The PREPARE Act could represent an area of agreement.

“Americans across the political spectrum recognize that now is the time for cannabis reform, and the federal government should be ready to embrace and lead this change,” Jeffries said. “Since the failed war on drugs began over 50 years ago, the prohibition of marijuana has ruined lives, families and communities—particularly communities of color.”

“The PREPARE Act is one of the bipartisan solutions that will lay the groundwork to finally right these wrongs in a way that advances public safety and boosts our economy,” he said. “I am grateful to Congressman Joyce for reintroducing this important bill and his leadership to help the federal government be ready for the inevitable end to cannabis prohibition.”

While legalization was introduced last Congress, with Democrats in control of both chambers plus the White House, they did not advance on the Senate side, with leadership acknowledging the challenge of meeting a 60-vote threshold with a narrow majority.

Advocates of fewer restrictions on the federal level are also closely following developments on a package of incremental reforms that’s expected to contain marijuana banking and expungements legislation. Efforts to push that through last session similarly stalled out.

The PREPARE Act, meanwhile, is substantially identical to the version the same lawmakers filed last Congress, with just a few minor changes to the commission’s responsibilities and legislative appointments.

The Bill aims to provide for:

A “Commission on the Federal Regulation of Cannabis” it requires that within 30 days of the bill’s enactment that this is established by the attorney general. The commission would be responsible for understanding federal and state regulatory models for alcohol making recommendations about how they could advise marijuana regulations.

One key thing the commission’s report must address is the impact of marijuana criminalization, particularly as it concerns minority, low-income and veteran communities.

The panel would also examine the “lack of consistent regulations for cannabis product safety, use and labeling requirements,” including those related to youth safety, as well as the “lack of guidance for cannabis crop production, sale, intrastate, interstate, and international trade. “

It would also be required to make recommendations on how to undo cannabis-related banking and research barriers and also address measures to ensure the “successful coexistence of individual hemp and cannabis industries, including prevention of cross pollination of cannabis and hemp products.”

The panel would be mandated to study and make recommendations on “efficient cannabis revenue reporting and collecting, including efficient and tenable federal revenue frameworks.”

The panel would be required to issue a report to Congress within 12 months.

As part of the bill’s directive to assess risk and safety standards, the bill was revised for the current Congress to make it so the commission would also have to look at “requirements to protect youth and reduce harms to youth.”

In the previous version, it was the responsibility of the House minority leader to choose a candidate who was “medically licensed with extensive expertise and demonstrated research into cannabis use and medical therapies.” Under the revised bill, the majority leader would be in charge of that.

The panel would also include representatives of:

Department of Health and Human Services

Department of Justice

Department of Agriculture

Department of Veterans Affairs

Department of Interior

Department of Education

Department of Labor

Department of Commerce

National Institutes of Health

Alcohol and Tobacco Tax and Trade Bureau

Food and Drug Administration

Internal Revenue Service

Bureau of Alcohol, Tobacco, Firearms and Explosives

National Highway Traffic Safety Administration

Occupational Safety and Health Administration

National Institute of Standards and Technology

Small Business Administration

U.S. Trade Representative

Some of the appointments would be made by the congressional leaders, and others would be selected by the attorney general. The bill also contains a stipulation that, “if after the commission is appointed there is a partisan imbalance of commission members, the congressional leaders of the political party with fewer members on the commission shall jointly name additional members to create partisan parity on the commission.”

The panel must also include a person formerly incarcerated for a non-violent cannabis use or possession crime, a substance use disorder prevention expert, a representative from a trade organization or nonprofit representing highly regulated adult goods and consumer package goods and two people who have worked to develop state-level regulatory systems.

Attorney General Merrick Garland, for his part, has repeatedly said that he doesn’t feel that intervening in states that have legalized cannabis is an appropriate use of Justice Department resources.

He said last month that the federal government is “still working on a marijuana policy” amid an ongoing administrative review into cannabis scheduling that President Joe Biden directed late last year.

Take Away

While states continue to move forward and pass laws allowing both recreational and medical marijuana, federal laws prevent access to the banking system, US postal service, and make them potentially prosecutable under federal law.

The re-introduced bill aims to open the door for these businesses to operate more freely, while at the same time make amends for harsh punishments imposed on those convicted of marijuana use in the past.

Overall, federal legalization of cannabis would energize the medical and recreational marijuana industries in the US, providing greater access, reduced legal risks, increased investment, tax revenue, and research opportunities.

Paul Hoffman

Managing Editor, Channelchek

https://joyce.house.gov/posts/joyce-jeffries-reintroduce-bipartisan-legislation-to-prepare-for-inevitable-end-to-federal-cannabis-prohibition

https://jeffries.house.gov/legislation/

Schwazze (SHWZ) – Expanding Into Colorado Medical


Wednesday, April 19, 2023

Schwazze (OTCQX:SHWZ, NEO:SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Joe Gomes, Managing Director – Generalist Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Acquisition. Piggybacking on a year’s worth of operating experience in the New Mexico medical cannabis market, Schwazze is expanding into the Colorado medical cannabis market with the acquisition of medical cannabis dispensary Standing Akimbo located in Denver. Standing Akimbo management will remain with Schwazze.

Transaction Details. Schwazze is paying $10.54 million for the acquisition, split into $1.0 million of cash, $5.54 million of SHWZ common stock, and $4.0 million of deferred cash payments. The transaction is expected to close in the third quarter of 2023. This brings the number of Schwazze dispensaries in Colorado to 29, assuming all announced acquisitions close.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MustGrow Biologics Corp. (MGROF) – A New Product


Wednesday, April 19, 2023

Joe Gomes, Managing Director – Generalist Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A New Product. Yesterday, MustGrow announced an additional area of sustainable agriculture opportunity that the Company is pursuing in the soil amendment and biofertility markets. These plant-based programs focus on soil and microbiome health, nutrient and water use efficiencies, and plant yields.

Introducing TerraSante. Utilizing multiple technologies derived from novel plant-based extracts from mustard and potentially other sources, TerraSante contains nutritious plant proteins and carbohydrates that feed soil microbes, potentially improving beneficial microbial activity and ensuring long-term sustainable soil health. MustGrow is initially pursuing TerraSante branded registrations in North America for soil amendment applications, followed by formulations and brands targeting the biofertility markets.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MAIA Biotechnology (MAIA) – Publication Details Efficacy and Mechanism In HCC Models


Wednesday, April 19, 2023

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Study Published In Peer-Reviewed Journal. MAIA Biotech announced that a new study testing THIO in models of liver cancer (HCC, hepatocellular carcinoma) has been published in the peer-reviewed journal Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR). The data shows efficacy and durability, with additional data on the mechanism of action for THIO treatment in HCC. We believe this provides strong support for mechanism of action and prospects for HCC in the Phase 2 THIO-102 trial, expected to begin later in 2023.

New Data Tested Monotherapy and Combinations. The study tested THIO with checkpoint inhibitors and anti-VEGF (anti-angiogenesis) drugs in advanced tumors. Data shows an anti-tumor response in HCC, detailing its activation of immune pathways and increases in immune cellular response. These results correlate with data seen in previous NSCLC studies.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Largo Inc. (LGO) – Largo announces 2023-1Q production and sales


Wednesday, April 19, 2023

Largo has a long and successful history as one of the world’s preferred vanadium companies through the supply of its VPURE™ and VPURE+™ products, which are sourced from one of the world’s highest-grade vanadium deposits at the Company’s Maracás Menchen Mine in Brazil. Aiming to enhance value creation at Largo, the Company is in the process of implementing a titanium dioxide pigment plant using feedstock sourced from its existing operations in addition to advancing its U.S.-based clean energy division with its VCHARGE vanadium batteries. Largo’s VCHARGE vanadium batteries contain a variety of innovations, enabling an efficient, safe and ESG-aligned long duration solution that is fully recyclable at the end of its 25+ year lifespan. Producing some of the world’s highest quality vanadium, Largo’s strategic business plan is based on two pillars: 1.) leading vanadium supplier with an outlined growth plan and 2.) U.S.-based energy storage business support a low carbon future.

Michael Heim, Senior Vice President – Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Largo announced reduced production but increased sales. Largo announced 2023-1Q V2O5 production of 2,111 tonnes (23 tonnes/day) near the upper end of guidance, albeit slightly below that in used our models. The 14% decrease in production versus the same period last year come due to heavy rain in the early part of the quarter, planned maintenance, and the transition of a mining contractor. These factors were known and reflected in our estimates. Production levels also reflect a decline in effective grade to 0.81% from 1.27% as less vanadium was produced despite a 13% increase in mined ore. 

Sales rose despite lower production as the company sold inventory and purchased material. V2O5 equivalent sales were 2,849 tonnes in the quarter, up 28% over last year sales of 2,232 tonnes and well above guidance of 2,300-2,500 tonnes and our projections that assumed sales near production levels. Sales include 245 tonnes of purchased material versus only 79 tonnes last year. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Tokens.com Corp. (SMURF) – Step Towards Full Ownership of Metaverse Group


Wednesday, April 19, 2023

Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.

Joe Gomes, Managing Director – Generalist Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

An Offer. Yesterday, Tokens.com announced an agreement with the Board of Directors of Metaverse Group to acquire all issued and outstanding shares that Tokens.com does not already own. Currently, the Company owns roughly 55.2% of Metaverse Group, or 50.2% on a diluted basis, and Tokens.com will issue 24.38 million common shares for the acquisition, if approved, equal to approximately USD$3.5 million as of yesterday’s closing price.

The Offer Continued. Each minority Metaverse Group shareholder will receive approximately 0.34 Tokens.com shares per Metaverse Group share. The offer is pending approval of Metaverse Group shareholders and a meeting will take place on April 26th, 2023, as well as approval by the NEO Exchange, and is expected to close in May 2023. We expect the offer will be approved by the shareholders and the exchange.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Is the NRC Overstepping on Fusion?

Image: Deuterium ionized into fusion plasma lets off a fuchsia glow (Helion)

A Hybrid Regulatory Approach by the NRC on Fusion

A fusion energy system is a power plant that harnesses energy released from the fusion of atomic nuclei to generate electricity. New commercial fusion designs intended to assist in the future of mass power, are being engineered with very little regulatory framework for them to design toward. The US Nuclear Regulatory Commission (NRC) Chairman Christopher Hanson wants the regulatory framework for fusion energy systems based on its existing process for licensing the use of byproduct materials. A new framework may add to the number of companies designing and developing pilot reactors.

The process of fusion involves bringing together atomic nuclei under high temperatures and pressures to create a plasma state, where the positively charged nuclei fuse to form heavier elements, releasing a large amount of energy in the process. Unlike traditional nuclear power plants, which rely on nuclear fission, fusion power plants do not produce long-lived radioactive waste and have a virtually limitless supply of fuel in the form of hydrogen isotopes found abundantly in seawater. Fusion energy, holds great promise as a clean and sustainable source of energy as fossil fuels fall from favor.

“Dozens” of companies are developing pilot-scale commercial fusion designs, according to NRC Chair Christopher Hanson. In a press release by the NRC last Friday Hanson said the “precise future” for fusion in the USA is uncertain, the agency should provide “as much regulatory certainty as possible given what we know today.” The reason provided in the release said,”Licensing near-term fusion energy systems under a byproduct material framework will protect public health and safety with a technology-neutral, scalable regulatory approach.”

Is this overstepping on the part of the NRC? The Commission describes a fusion system as a device that contains nuclear fusion reactions as well as associated radioactive materials and supporting structures, systems and components – would generate electricity from the energy released when hydrogen atoms are combined to form helium, rather than the splitting, or fission, of uranium atoms. This very definition causes the systems to fall outside the requirements to be regulated by NRC as nuclear reactors, because they do not involve special nuclear material (plutonium, uranium-233 or enriched uranium) and cannot produce the self-sustained neutron chain reaction that defines nuclear fission reactors under NRC regulations.

The NRC staff outlined suggested options earlier in 2023 for the licensing and regulation of fusion systems.  It categorized them as “utilization facilities”, with a novel regulatory framework developed to address associated specific hazards. These include a byproduct material approach, which adds to the existing regulations for byproduct material licenses. It also included a hybrid framework where the decision on whether a byproduct material or a utilization facility approach would be most appropriate for a particular system based on the potential dangers and hazards inherent to it – it would need to define what would be most applicable for that system. The NRC staff supported the use of a hybrid system in its submission.

Tritium and other radioactive materials which occur or are used in fusion systems have been categorized by the NRC as byproduct material. The NRC has now directed its staff to create a regulatory framework for fusion systems built on the agency’s existing process for licensing the use of such materials.

Image: @Helion_Energy (Twitter)

The Commission will move forward with a “limited revision” to materials licensing regulations, including consideration of whether the revision should include a new category specifically for fusion energy systems. The rule, according to the NRC, take into account fusion systems “that already have been licensed and are being regulated by the Agreement States, as well as those that may be licensed prior to the completion of the rulemaking”. The commission staff is also exected to expand materials license guidance to cover fusion systems across the US.

The US Department of Energy (DOE) announced in 2022 up to $50 million of federal funding to support experimental research in fusion energy science as part of the Biden administration’s vision to accelerate fusion energy. New designs are speeding along as a few fusion systems are likely reach design proof-of-concept, and even net power production later this decade, with deployment projected to follow in the 2030s, according to the NRC.

One US fusion system developer, Helion Energy, expressed support for the NRC’s announcement. “This approach provides a clear and effective regulatory path for our team to deploy clean, safe fusion energy,” the company said on Twitter.

Sources

https://www.nrc.gov/cdn/doc-collection-news/2023/23-029.pdf

https://mobile.twitter.com/Helion_Energy

https://www.utilitydive.com/news/nrc-regulations-nuclear-fusion-energy-systems/647766/

https://world-nuclear-news.org/Articles/NRC-starts-work-on-regulatory-framework-for-fusion

https://thebreakthrough.imgix.net/BTI-Fusion-Whitepaper.pdf

Artificial Intelligence, Speculation, and ‘Technical Debt’

Image Credit: Focal Foto (Flickr)

AI Has Social Consequences, But Who Pays the Price?

As public concern about the ethical and social implications of artificial intelligence keeps growing, it might seem like it’s time to slow down. But inside tech companies themselves, the sentiment is quite the opposite. As Big Tech’s AI race heats up, it would be an “absolutely fatal error in this moment to worry about things that can be fixed later,” a Microsoft executive wrote in an internal email about generative AI, as The New York Times reported.

In other words, it’s time to “move fast and break things,” to quote Mark Zuckerberg’s old motto. Of course, when you break things, you might have to fix them later – at a cost.

In software development, the term “technical debt” refers to the implied cost of making future fixes as a consequence of choosing faster, less careful solutions now. Rushing to market can mean releasing software that isn’t ready, knowing that once it does hit the market, you’ll find out what the bugs are and can hopefully fix them then.

However, negative news stories about generative AI tend not to be about these kinds of bugs. Instead, much of the concern is about AI systems amplifying harmful biases and stereotypes and students using AI deceptively. We hear about privacy concerns, people being fooled by misinformation, labor exploitation and fears about how quickly human jobs may be replaced, to name a few. These problems are not software glitches. Realizing that a technology reinforces oppression or bias is very different from learning that a button on a website doesn’t work.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Casey Fiesler, Associate Professor of Information Science, University of Colorado Boulder.

As a technology ethics educator and researcher, I have thought a lot about these kinds of “bugs.” What’s accruing here is not just technical debt, but ethical debt. Just as technical debt can result from limited testing during the development process, ethical debt results from not considering possible negative consequences or societal harms. And with ethical debt in particular, the people who incur it are rarely the people who pay for it in the end.

Off to the Races

As soon as OpenAI’s ChatGPT was released in November 2022, the starter pistol for today’s AI race, I imagined the debt ledger starting to fill.

Within months, Google and Microsoft released their own generative AI programs, which seemed rushed to market in an effort to keep up. Google’s stock prices fell when its chatbot Bard confidently supplied a wrong answer during the company’s own demo. One might expect Microsoft to be particularly cautious when it comes to chatbots, considering Tay, its Twitter-based bot that was almost immediately shut down in 2016 after spouting misogynist and white supremacist talking points. Yet early conversations with the AI-powered Bing left some users unsettled, and it has repeated known misinformation.

When the social debt of these rushed releases comes due, I expect that we will hear mention of unintended or unanticipated consequences. After all, even with ethical guidelines in place, it’s not as if OpenAI, Microsoft or Google can see the future. How can someone know what societal problems might emerge before the technology is even fully developed?

The root of this dilemma is uncertainty, which is a common side effect of many technological revolutions, but magnified in the case of artificial intelligence. After all, part of the point of AI is that its actions are not known in advance. AI may not be designed to produce negative consequences, but it is designed to produce the unforeseen.

However, it is disingenuous to suggest that technologists cannot accurately speculate about what many of these consequences might be. By now, there have been countless examples of how AI can reproduce bias and exacerbate social inequities, but these problems are rarely publicly identified by tech companies themselves. It was external researchers who found racial bias in widely used commercial facial analysis systems, for example, and in a medical risk prediction algorithm that was being applied to around 200 million Americans. Academics and advocacy or research organizations like the Algorithmic Justice League and the Distributed AI Research Institute are doing much of this work: identifying harms after the fact. And this pattern doesn’t seem likely to change if companies keep firing ethicists.

Speculating – Responsibly

I sometimes describe myself as a technology optimist who thinks and prepares like a pessimist. The only way to decrease ethical debt is to take the time to think ahead about things that might go wrong – but this is not something that technologists are necessarily taught to do.

Scientist and iconic science fiction writer Isaac Asimov once said that sci-fi authors “foresee the inevitable, and although problems and catastrophes may be inevitable, solutions are not.” Of course, science fiction writers do not tend to be tasked with developing these solutions – but right now, the technologists developing AI are.

So how can AI designers learn to think more like science fiction writers? One of my current research projects focuses on developing ways to support this process of ethical speculation. I don’t mean designing with far-off robot wars in mind; I mean the ability to consider future consequences at all, including in the very near future.

This is a topic I’ve been exploring in my teaching for some time, encouraging students to think through the ethical implications of sci-fi technology in order to prepare them to do the same with technology they might create. One exercise I developed is called the Black Mirror Writers Room, where students speculate about possible negative consequences of technology like social media algorithms and self-driving cars. Often these discussions are based on patterns from the past or the potential for bad actors.

Ph.D. candidate Shamika Klassen and I evaluated this teaching exercise in a research study and found that there are pedagogical benefits to encouraging computing students to imagine what might go wrong in the future – and then brainstorm about how we might avoid that future in the first place.

However, the purpose isn’t to prepare students for those far-flung futures; it is to teach speculation as a skill that can be applied immediately. This skill is especially important for helping students imagine harm to other people, since technological harms often disproportionately impact marginalized groups that are underrepresented in computing professions. The next steps for my research are to translate these ethical speculation strategies for real-world technology design teams.

Time to Hit Pause?

In March 2023, an open letter with thousands of signatures advocated for pausing training AI systems more powerful than GPT-4. Unchecked, AI development “might eventually outnumber, outsmart, obsolete and replace us,” or even cause a “loss of control of our civilization,” its writers warned.

As critiques of the letter point out, this focus on hypothetical risks ignores actual harms happening today. Nevertheless, I think there is little disagreement among AI ethicists that AI development needs to slow down – that developers throwing up their hands and citing “unintended consequences” is not going to cut it.

We are only a few months into the “AI race” picking up significant speed, and I think it’s already clear that ethical considerations are being left in the dust. But the debt will come due eventually – and history suggests that Big Tech executives and investors may not be the ones paying for it.